Panel Disdussion

More documents

Recommendations

Info

3rd International Congress 3rd International of Nuclear Congress Medicine of Nuclear & 15th Medicine Iranian Annual & 15th Iranian Congress Annual of Nuclear Congress Medicine of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical Sciences of Medical 19-21 Sciences May 201119-21 May 2011 Synthesis and biodistribution studies of 67Ga-DOTAtrastuzumab as a diagnostic radioimmunoconjugate for oncology imaging by SPECT Behrooz Alirezapour 1 , Amir Reza Jalilian 1 , Mohammad javad Rasaee 2 , Saeed Rajabifar 1 , Kamal Yavari 1 , Javad Mohammadnejad 1 , Mohammad Reza Aboudzadeh 1 , Fatemeh Bolourinovin 1 , Sedigheh Moradkhani 1 , Mojtaba Fathi 2 1 Nuclear Science and Technology Research Institute (NSTRI) 2 Tarbiat Modares University(TMU) Introduction: Radiolabeled monoclonal antibodies have shown great promise for cancer diagnosis and therapy. Trastuzumab (trade name; Herceptin) is a humanized IgG1 monoclonal antibody directed against the extracellular domain of the Human Epidermal Growth Factor Receptor 2(HER2). HER 2 receptor is over expressed in 20-30% of the early-stage breast cancers and these patients may be candidates for Herceptin treatment. we attempted to label trastuzumab with radioactive gallium(67Ga) 67Ga is cyclotron produced, decays by electron capture (EC) with t1/2 = 77.9h accompanied with γ-rays, mainly 93, 184 and 296 keV, and is suitable for SPECT imaging. In the present study, 67Ga labeled trastuzumab was prepared followed by the biodistribution studies in normal mice. Methods: Herceptin was conjugated with DOTA-NHS-ester (Macrocyclics), purified by molecular filtration, the average number of DOTA conjugated per mAb was calculated and total concentration was determined by spectrophotometrically. DOTA-Trastuzumab was labeled with 67Ga then Radiochemical purity, integrity of protein after radiolabeling and stability of 67Ga -DOTA-Trastuzumab were determined. The biodistribution studies was performed in normal rats (67Ga -DOTA-Trastuzumab i.v., 75 ± 5.5 µCi, 30min, 2h, 4h, 24h, 48h, 72h). Result: The radioimmunoconjugate was prepared with a radiochemical purity of 88% (RTLC). The average chelate to antibody ratio(c/a) for the conjugate used in this study was 5.8:1. The final compound was stable in presence of PBS at 37ÂºC and room temperature.The sample were showed to have similar patterns of migration in the gel electrophoresis.The accumulation of the radiolabeled antibody in lungs, liver, spleen and other tissues demonstrates a similar pattern to the other radiolabeled anti-HER2 immunoconjugates. Conclusion: 67Ga-DOTA-Trastuzumab is potentially good probe for diagnosis and treatment studies of HER2 expression in oncology by SPECT. Keywords: 67Ga DOTA, Radioimmunoconjugate, Trastuzumab, HER2 142
3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of Congress of Nuclear Medicine Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011 Calculation of relative dose of human body produced by fusion neutrons using MCNP code Masoode Abdolahzade 1 , Masome Nonbede 2 , Yaser kasesaz 3 , Amir Moslehi 3 , Davoode Gasemabadi 1 , Mohsen Shayeste 1 1 Imam Hossein University 2 Tehran Center Azad University 3 Atomic Energy Organization of Tehran In this paper a simulated phantom of adult human body using Monte Carlo method and MCNP code, is used for the neutron effective dose equivalent calculation. The plasma focus device emits neutrons with 2.45 MeV energy in D-D fusion reactions. Effective dose equivalent is calculated in four geometry, AP, PA, LLAT, RLAT, for some organs by the weight coefficients of radiation and the tissue weight factor reported by ICRP. The results are compared by the occupational exposures effective dose equivalent recommended by ICRP. Keywords: Neutron emission, Dosimetery, Phantom, CodeMCNP Simulation 143
Page 1 and 2:
3rd International Congress of Nucle
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
3rd International Congress of of Nu
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92: 3rd International Congress of of Nu
Page 141: 3rd International Congress of of Nu
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
show all

Panel Disdussion

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?